Clinical Trials Logo
  1. Home
  2. Emphysema
  3. NCT00261833

Zemaira in Subjects With Emphysema Due to Alpha1-Proteinase Inhibitor Deficiency

Emphysema Clinical Trial

Official title:
A Randomized, Placebo-Controlled, Double-Blind, Multicenter Phase III/IV Study to Compare the Efficacy and Safety of 60mg/kg Body Weight of Zemaira® Weekly I.V. Administration With Placebo Weekly I.V. Administration in Chronic Augmentation and Maintenance Therapy in Subjects With Emphysema Due to Alpha1-Proteinase Inhibitor Deficiency

Clinical Trial Summary

This is a randomized, placebo-controlled, double-blind, multicenter phase III/IV study to compare the efficacy and safety of Zemaira® with placebo in subjects with emphysema due to alpha1-proteinase inhibitor deficiency. The effect of Zemaira® on the progression of emphysema will be assessed by the decline of lung density, measured by computed tomography (CT).

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00261833
Study type Interventional
Source CSL Behring
Contact
Status Completed
Phase Phase 4
Start date March 2006
Completion date September 2012
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05825261 - Exploring Novel Biomarkers for Emphysema Detection
Completed NCT02914340 - REACH SVS Control Patient Cross-Over Study N/A
Completed NCT02999685 - Home-based Health Management of Chronic Obstructive Lung Disease (COPD) Patients N/A
Completed NCT02238327 - Longitudinal Evaluation of HIV-associated Lung Disease Phenotypes
Completed NCT02232841 - Electrical Impedance Imaging of Patients on Mechanical Ventilation N/A
Withdrawn NCT01908933 - Study of the AeriSeal System Treatment in Patients With Advanced Non-Upper Lobe Predominant Heterogeneous Emphysema Phase 3
Completed NCT01615484 - Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability N/A
Completed NCT01476995 - Prognostic Indicators as Provided by the EPIC ClearView N/A
Completed NCT01710449 - Evaluation of Regional Ventilation Using 19F MRI of Inert Perfluorinated Gases Mixed With Oxygen Phase 1
Suspended NCT00523094 - Vibration Response Imaging (VRI) in Patients That Are Candidates for Undergoing Pulmonary Operation Procedure N/A
Completed NCT00475007 - Clinical Trial to Evaluate the Safety and Effectiveness of the IBV® Valve System for the Treatment of Severe Emphysema N/A
Recruiting NCT00129350 - Assessment of Heart and Heart-Lung Transplant Patient Outcomes Following Pulmonary Rehabilitation Phase 1
Completed NCT01953523 - Safety and Clinical Outcomes Study: SVF Deployment for Orthopedic, Neurologic, Urologic, and Cardio-pulmonary Conditions N/A
Completed NCT00000621 - Feasibility of Retinoic Acid Treatment in Emphysema (FORTE) Phase 2
Completed NCT00005292 - Alpha1-antitrypsin Deficiency Registry N/A
Recruiting NCT04537182 - Surgical Compared to Bronchoscopic Lung Volume Reduction in Patients With Severe Emphysema N/A
Active, not recruiting NCT02713347 - Advancing Symptom Alleviation With Palliative Treatment N/A
Recruiting NCT04302272 - STRIVE Post-Market Registry Study
Completed NCT04435327 - Lung Damage Caused by SARS-CoV-2 Pneumonia (COVID-19)
Completed NCT03636347 - A 12-week Study Treating Participants Who Have alpha1-antitrypsin-related COPD With Alvelestat (MPH966) or Placebo. Phase 2